Search

Rss Posts

Rss Comments

Login

 

Anemia Triples Risk of Local Recurrence in Breast Cancer Patients

Apr 25

By Nicholas Mulcahy, HealthDay ReporterTHURSDAY, April 3 (HealthDay News) — Breast cancer patients who develop anemia during chemotherapy face almost three times the risk of a recurrence in the same area of the affected breast, new research suggests.

The Austrian study was a re-analysis of information from a clinical trial that took place in the 1990s. Importantly, the findings also indicated that anemia did alter overall survival or significantly increase the risk of cancer occurring in a patient’s other breast or spreading elsewhere in the body. Anemia, a common side effect of chemotherapy, is a low red blood cell count that can cause fatigue and reduced quality of life.

“This study is definitely not aimed at changing current practice,” said study author Dr. Peter Dubsky, of the Medical University of Vienna. “This is a retrospective analysis that has yielded quite controversial data. The conclusion from our study is aimed at experimental and clinical oncologic research. Anemia is associated with a high likelihood of tumor hypoxia [too little oxygen in the blood].”

The chemotherapy used in the study was a combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). The problems of anemia and related local recurrence are probably not limited to just this form of chemotherapy, noted Dr. Douglas Yee, director of the University of Minnesota Cancer Center. “I think this effect would be seen with any chemotherapy.”

CMF is no longer commonly used in the treatment of breast cancer and has been replaced by other forms of chemotherapy such as taxanes, added Dr. Barry C. Lembersky, a clinical associate professor of medicine at the University of Pittsburgh School of Medicine. Also, there is a trend in breast cancer treatment to use chemotherapy less often, he said.

“Nowadays, there is a more selective use of chemotherapy, which tends to be used when a tumor is not stimulated by estrogen, lymph nodes are involved, or the genetic/clinical profile is suited for chemotherapy,” he explained.

In the Austrian study, CMF therapy was used as an additional treatment in 424 patients who were premenopausal and who underwent surgery as their main treatment for early-stage breast cancer. All had estrogen receptor-positive malignancies. The findings were published in the April 1 issue of Clinical Cancer Research.

The surgery was either a breast-conserving lumpectomy, which required additional radiation, or a modified radical mastectomy, for which radiation was optional. The radiation was given in the middle of chemotherapy treatment process, which is now an outdated method, Yee noted. “We tend not to do this kind of sandwich technique anymore,” he explained.

After an average follow-up of 61 months, 39 local relapses occurred among the 424 women: 6.9 percent in patients without anemia and 19.5 percent in patients with anemia. The five-year rates of local relapse were 8.2 percent among patients without anemia and 19.6 percent among patients with anemia.

In addition to anemia, two other factors — an older age at diagnosis and positive lymph node status — significantly increased the risk of a local recurrence of breast cancer. According to an analysis of the range of factors examined in the study, patients with anemia had a 2.96-fold increased relative risk of a local recurrence.

Since the Austrian research was conducted, the treatment of anemia in breast cancer patients has become controversial, Lembersky noted.

“Erythropoietin-stimulating agents are indicated for use by the FDA [U.S. Food and Drug Administration] when red blood cell counts are too low,” he said. “However, there is now controversy about their use due to the possible increase in tumor growth in breast cancer.”

Dubsky agreed.

“I am sure you are aware of the recent pitfalls in the use of erythropoiesis-stimulating agents (ESAs),” he said. “Given this context, we should start discussing anemia more in the context of tumor hypoxia and look for targets that are distinct from erythropoiesis.”

More informationHere’s more on the treatment of early-stage breast cancer.

content by:

Healthday

SOURCES: Peter Dubsky, M.D., Department of Surgery, Medical University of Vienna, Austria; Douglas Yee, M.D., director, University of Minnesota Cancer Center, Minneapolis; Barry C. Lembersky, M.D., clinical associate professor, medicine, University of Pittsburgh School of Medicine; April 1, 2008, Clinical Cancer Research

Copyright © 2008 ScoutNews, LLC. All rights reserved.

Traditional Chinese Medicinal Herbs May Help Women With Breast Cancer

Apr 25

ScienceDaily (Apr. 18, 2007) — Using Chinese herbs either alone or in conjunction with chemotherapy may help protect a breast cancer patient’s bone marrow and immune system, as well as improving the woman’s overall quality of life.

Sixty per cent of women undergoing chemotherapy for breast cancer experience a range of significant short term side effects. These include nausea, vomiting and fatigue, as well as inflammation of the gut lining, decreased numbers of red and white blood cells and decreased numbers of blood platelets.

Chinese medicinal herbs include mixtures of herbal compounds or extracts from herbs, and they are prescribed to counteract the side effects of chemotherapy. This Cochrane Systematic Review set out to see if there is conventional evidence indicating that these medicines are safe and whether there is evidence that the medicines are effective.

The researchers identified seven randomised studies involving 542 patients with breast cancer. By analysing these data, the researchers concluded that there was no evidence that the Chinese medicinal herbal treatment caused harm, and some evidence that it might reduce side effects.

“Further trials are needed before the effects of traditional Chinese medicines for people with breast cancer can be evaluated with any real confidence,” says Assistant Professor Jing Li, who works at the Chinese Cochrane Centre in Chengdu, China.

John Wiley & Sons, Inc. (2007, April 18). Traditional Chinese Medicinal Herbs May Help Women With Breast Cancer. ScienceDaily. Retrieved December 4, 2007.

Chemobrain: When cancer treatment disrupts your thinking and memory

Dec 05

From MayoClinic.com http://www.chemobraininfo.org

For years people undergoing cancer treatment have described their minds as being in a fog — unable to concentrate and remember details about their everyday lives. Doctors and researchers knew something was wrong, but they couldn’t pinpoint what it was.

Research now shows that what these people are experiencing is called mild cognitive impairment — the loss of the ability to remember certain things, learn new skills and complete certain tasks. The cause of mild cognitive impairment during cancer treatment still isn’t clear, nor is it clear how often it happens or what may trigger it. Doctors aren’t sure what they can do about it.

But that doesn’t mean there isn’t any hope. Recognize mild cognitive impairment and its association with cancer treatment, and talk to your doctor about your symptoms or concerns. Taking small steps can help you cope with changes in your memory during treatment.

What is chemobrain?

The terms “chemobrain” and “chemofog” refer to cognitive changes during and after cancer diagnosis and treatment. Though these terms imply a relation to chemotherapy, it isn’t clear that chemotherapy is responsible. Women with breast cancer who underwent chemotherapy were the first group to bring these symptoms to light, as more started mentioning their symptoms to their doctors. It isn’t clear whether chemotherapy, or other factors such as stress and hormonal fluctuations, cause the changes in memory and thinking. What is clear is that some people with cancer do notice increased difficulties with certain mental tasks during and after cancer treatment.

In general, researchers have found that chemotherapy can affect your cognitive abilities in the following ways:

bullet

Word finding. You might find yourself reaching for the right word in conversation.

bullet

Memory. You might experience short-term memory lapses, such as not remembering where you put your keys or what you were supposed to buy at the store.

bullet

Multitasking. Many jobs require you to manage multiple tasks during the day. Multitasking is important at work as well as at home — for example, talking with your kids and making dinner at the same time. Chemotherapy may affect how well you’re able to perform multiple tasks at once.

bullet

Learning. It might take longer to learn new things. For example, you might find you need to read paragraphs over a few times before you get the meaning.

bullet

Processing speed. It might take you longer to do tasks that were once quick and easy for you.

About 20 percent to 30 percent of people undergoing chemotherapy will experience cognitive impairment, though some studies report that at least half the participants had memory problems. One study found 35 percent of women with breast cancer had memory problems before beginning chemotherapy, so it’s not clear how or if memory changes are related to cancer treatment. Signs and symptoms of these memory changes can last for a year or two after your treatment.

Changes in memory during and after treatment may be very subtle. You might notice changes during your everyday tasks and as you start working again after treatment. The memory changes are often so subtle, in fact, that researchers find that people who report having memory difficulties tend to score in the normal ranges on tests of their cognitive ability. That makes it more difficult to understand, diagnose and treat the memory changes.

What causes the memory changes?

Doctors don’t know what causes the cognitive changes associated with chemotherapy. It was previously thought that chemotherapy drugs didn’t enter your brain, but were kept out by the blood-brain barrier, which separates chemicals that should be in your brain from those that shouldn’t. But some researchers now suspect some chemotherapy drugs may be able to slip past the blood-brain barrier. This could potentially affect your brain and your memory.

It isn’t clear which chemotherapy drugs are more likely to cause memory changes or if higher doses pose a bigger risk than do smaller ones. And it isn’t possible to predict who’s more likely to have cognitive impairment after chemotherapy.

A number of factors can cause temporary memory problems in people undergoing chemotherapy — making it difficult to identify the so-called chemobrain from the normal stresses of treatment. Temporary memory problems can, for the most part, be treated. Causes include:

bullet

Low blood counts. If your blood counts are low, you might feel tired, making it difficult to concentrate.

bullet

Stress. Being diagnosed with cancer and starting treatment is stressful. Stress also makes concentrating difficult.

bullet

Medication to treat side effects. Certain medications for treating side effects including nausea and vomiting may cause drowsiness. When you’re tired, it may take longer to complete tasks.

bullet

Lingering depression. Depression is common in people with cancer. If your depression continues after your treatment, you might find it difficult to pay attention.

bullet

Lingering fatigue. Fatigue is a side effect of several types of cancer treatment, including chemotherapy. Your fatigue might end when your cancer treatment ends, though it also can continue after treatment.

bullet

Hormonal changes. Many cancer treatments may alter the normal hormonal balance in your body, causing cognitive changes. Hormonal changes are a side effect of some treatments and, with other treatments, are the intended way to treat your cancer.

bullet

Pain medications. Some pain medications cause drowsiness and difficulty concentrating. For most people, these side effects diminish or disappear once a proper dose of pain medication is established.

Talk to your doctor about your memory problems. If your symptoms are caused by medications or stress, your doctor can treat those symptoms and help get your mind back on track.

How are memory changes treated?

If you have impaired memory, your doctor may first try to rule out other causes of memory problems, such as stress and depression. Currently no medications exist to treat cognitive impairment associated with cancer and its treatment. Researchers are investigating whether medications for such disorders as depression, attention-deficit hyperactivity disorder (ADHD) and dementia could prove effective.

You can help yourself cope with the changes in your memory by taking a few simple steps. You might want to:

bullet

Exercise your body. Aerobic exercise helps your mood and can make you feel more alert. Both can help you when it comes to concentrating.

bullet

Exercise your mind. Give your mind a workout by learning a new skill, such as a new language. Take a class, participate in a book club or try crossword puzzles.

bullet

Track your memory problems. Keep a detailed diary of your memory problems throughout your day. Carry your diary with you and take quick notes on what medications you take and when. Note the time of day your memory problems occur and the situation.

bullet

Target specific problems. Use your daily diary to determine what influences your memory problems. If they tend to crop up in the early afternoon, you may be able to prepare yourself by not scheduling meetings or deadlines at that time of day.

bullet

Take notes. Make a list of everything you need to accomplish today and use it as a guide. Take detailed notes of things you need to remember.

bullet

Start a routine. Put your keys or other commonly misplaced objects in the same place every time you set them down. Try to keep the same schedule every day.

bullet

Talk about your problems. Be open with your friends and family about what you’re experiencing. Let them know your mind is moving a little slower these days and explain how they can help you. This can help you relax and make it easier for you to think and process information.

Find the coping method that’s best for you and stick to it. Talk to your doctor about your concerns. He or she might have some other suggestions.

What other types of cancer treatment might cause cognitive impairment?

Chemotherapy isn’t the only cancer treatment that may cause memory and thinking problems. Other treatments that might affect your brain include:

bullet

Hormone therapy. It isn’t clear whether women undergoing hormone therapy that alters the amount of estrogen in their bodies experience memory problems. Some studies link memory function to the amount of estrogen in the brain. Other studies haven’t found this link.

bullet

Immunotherapy. This experimental therapy stimulates your body’s own defenses to fight your cancer. Treatment with cytokines — a type of protein that causes inflammation in your body — may cause problems with memory, multitasking and processing information.

bullet

Radiation therapy. Radiation to your brain can impair your memory and your motor function, as well as your ability to learn new things and to multitask. Older adults and people receiving high doses of radiation are at a greater risk of memory problems. If you receive both chemotherapy and brain radiation, your risk is also higher.

As research continues, doctors expect to better understand which cancer treatments cause cognitive impairment and what they can do to limit their side effects.

Take note of any memory problems

If you’re currently undergoing cancer treatment or you’ve already been through treatment, take note of any problems you have remembering certain things or concentrating during certain tasks. Talk to your doctor about your signs and symptoms.

If you’ve yet to start your treatment, talk to your doctor about the risks of treatment, including cognitive impairment. Understanding your risks can help you make more informed decisions about your treatment.

October 13, 2006 http://www.chemobraininfo.org

White Blood Cell Booster May Help Cancer Patients Avoid Deadly Complications

Dec 05

ScienceDaily (Jul. 26, 2007) — Cancer patients who receive a drug that stimulates the growth of infection-fighting white blood cells may be significantly less likely to die from a chemotherapy-related complication characterized by fever and low white blood cell levels, according to a multi-institutional study led by researchers from the University of Rochester School of Medicine and Dentistry and the Duke Comprehensive Cancer Center.

“Chemotherapy drugs target cancer cells, but they can affect healthy cells as well, including infection-fighting white blood cells,” said Nicole M. Kuderer, M.D., a hematology-oncology fellow at Duke and lead author on the publication. “When patients’ white blood cell counts drop too low, they are at risk for dangerous infections that can cause death.”

Often, chemotherapy must be delayed, reduced in strength or halted when a patient’s white blood cell count is too low, potentially leading to poorer outcomes, she added.

“Patients taking a drug known as granulocyte colony-stimulating factor early in their chemotherapy were about half as likely to develop dangerously low white blood cell counts with fever, and half as likely to die from infection,” Kuderer said. “This study represents an important part of the effort to better treat this common complication in cancer patients receiving chemotherapy.”

The researchers published their findings in the July 20, 2007 issue of the Journal of Clinical Oncology. The work was part of research being conducted by the Awareness of Neutropenia in Chemotherapy (ANC) Study Group, a multi-institution, university-based network of investigators whose work is unrestrictedly funded by Amgen, the maker of a commonly utilized white blood cell booster that goes by the names Neupogen and Neulasta. Kuderer also receives funding from the National Institutes of Health.

This study compiled the results of 17 trials involving more than 3,000 patients receiving chemotherapy of varying intensity to treat several different types of cancers. The researchers found that nearly 40 percent of the patients who did not receive the white blood cell booster early in treatment developed the fever and low white blood cell levels called febrile neutropenia, compared to only 22 percent of the patients who took the drug in conjunction with their chemotherapy, Kuderer said.

While white blood cell boosters were known to help patients receiving very intense doses of chemotherapy, this study showed that the drugs are also a benefit to cancer patients receiving more common chemotherapy doses, Kuderer said.

Recently revised American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Center Network (NCCN) guidelines for the use of drugs such as Neulasta and Neupogen align with the conclusions reached by this study.

“The new guidelines recommend using these types of drugs when at-risk patients begin chemotherapy, rather than waiting for complications to develop,” said Jeffrey Crawford, M.D., chief of the division of medical oncology at Duke and one of the study’s investigators. “The new recommendations also suggest that we need better methods to identify patients who are at higher risk of developing febrile neutropenia, and future studies will be aimed at doing just that.”

White blood cell boosters can have side effects, including bone pain, which need to be reviewed and discussed with each patient, Crawford said.

Other investigators on the study include Gary Lyman of Duke and David Dale of the University of Washington.

Duke University Medical Center (2007, July 26). White Blood Cell Booster May Help Cancer Patients Avoid Deadly Complications. ScienceDaily. Retrieved December 4, 2007, from http://www.sciencedaily.com­ /releases/2007/07/070725110020.htm

Traditional Chinese Medicinal Herbs May Help Women With Breast Cancer

Dec 05

ScienceDaily (Apr. 18, 2007) — Using Chinese herbs either alone or in conjunction with chemotherapy may help protect a breast cancer patient’s bone marrow and immune system, as well as improving the woman’s overall quality of life.

Sixty per cent of women undergoing chemotherapy for breast cancer experience a range of significant short term side effects. These include nausea, vomiting and fatigue, as well as inflammation of the gut lining, decreased numbers of red and white blood cells and decreased numbers of blood platelets.

Chinese medicinal herbs include mixtures of herbal compounds or extracts from herbs, and they are prescribed to counteract the side effects of chemotherapy. This Cochrane Systematic Review set out to see if there is conventional evidence indicating that these medicines are safe and whether there is evidence that the medicines are effective.

The researchers identified seven randomised studies involving 542 patients with breast cancer. By analysing these data, the researchers concluded that there was no evidence that the Chinese medicinal herbal treatment caused harm, and some evidence that it might reduce side effects.

“Further trials are needed before the effects of traditional Chinese medicines for people with breast cancer can be evaluated with any real confidence,” says Assistant Professor Jing Li, who works at the Chinese Cochrane Centre in Chengdu, China.

John Wiley & Sons, Inc. (2007, April 18). Traditional Chinese Medicinal Herbs May Help Women With Breast Cancer. ScienceDaily. Retrieved December 4, 2007, from http://www.sciencedaily.com­ /releases/2007/04/070417194320.htm

Chemotherapy Fog Is No Longer Ignored as Illusion

Dec 05

By-Jane Gross

Published: April 29, 2007

On an Internet chat room popular with breast cancer survivors, one thread — called “Where’s My Remote?” — turns the mental fog known as chemo brain into a stand-up comedy act.

Michael Houghton for The New York Times

When she can’t remember where she parked her car, Lu Ann Hudson uses a key fob that sets off a beep in it.

Narayan Mahon for The New York Times

“I had a mind like a steel trap, and I ended up with a colander for a brain,” said Linda Lowen, who underwent chemotherapy 13 years ago.

Bob Hewitt for The New York Times

Terry-Lynne Jordan leaves herself voice mail messages as reminders.

One woman reported finding five unopened gallons of milk in her refrigerator and having no memory of buying the first four. A second had to ask her husband which toothbrush belonged to her.

At a family celebration, one woman filled the water glasses with turkey gravy. Another could not remember how to carry over numbers when balancing the checkbook.

Once, women complaining of a constellation of symptoms after undergoing chemotherapy — including short-term memory loss, an inability to concentrate, difficulty retrieving words, trouble with multitasking and an overarching sense that they had lost their mental edge — were often sent home with a patronizing “There, there.”

But attitudes are changing as a result of a flurry of research and new attention to the after-effects of life-saving treatment. There is now widespread acknowledgment that patients with cognitive symptoms are not imagining things, and a growing number of oncologists are rushing to offer remedies, including stimulants commonly used for attention-deficit disorder and acupuncture.

“Until recently, oncologists would discount it, trivialize it, make patients feel it was all in their heads,” said Dr. Daniel Silverman, a cancer researcher at the University of California, Los Angeles, who studies the cognitive side effects of chemotherapy. “Now there’s enough literature, even if it’s controversial, that not mentioning it as a possibility is either ignorant or an evasion of professional duty.”

That shift matters to patients.

“Chemo brain is part of the language now, and just to have it acknowledged makes a difference,” said Anne Grant, 57, who owns a picture-framing business in New York City. Ms. Grant, who had high-dose chemotherapy and a bone marrow transplant in 1995, said she could not concentrate well enough to read, garbled her sentences and struggled with simple decisions like which socks to wear.

Virtually all cancer survivors who have had toxic treatments like chemotherapy experience short-term memory loss and difficulty concentrating during and shortly afterward, experts say. But a vast majority improve. About 15 percent, or roughly 360,000 of the nation’s 2.4 million female breast cancer survivors, the group that has dominated research on cognitive side effects, remain distracted years later, according to some experts. And nobody knows what distinguishes this 15 percent.

Most oncologists agree that the culprits include very high doses of chemotherapy, like those in anticipation of a bone marrow transplant; the combination of chemotherapy and supplementary hormonal treatments, like tamoxifen or aromatase inhibitors that lower the amount of estrogen in women who have cancers fueled by female horemones; and early-onset cancer that catapults women in their 30s and 40s into menopause.

Other clues come from studies too small to be considered definitive. One such study found a gene linked to Alzheimer’s disease in cancer survivors with cognitive deficits. Another, using PET scans, found unusual activity in the part of the brain that controls short-term recall.

The central puzzle of chemo brain is that many of the symptoms can occur for reasons other than chemotherapy.

Abrupt menopause, which often follows treatment, also leaves many women fuzzy-headed in a more extreme way than natural menopause, which unfolds slowly. Those cognitive issues are also features of depression and anxiety, which often accompany a cancer diagnosis. Similar effects are also caused by medications for nausea and pain.

Dr. Tim Ahles, one of the first American scientists to study cognitive side effects, acknowledges that studies have been too small and lacked adequate baseline data to isolate a cause.

“So many factors affect cognitive function, and the kinds of cognitive problems associated with cancer treatment can be caused by many other things than chemotherapy,” said Dr. Ahles, the director of neurocognitive research at Memorial Sloan-Kettering Cancer Center in New York.

The new interest in chemo brain is, in effect, a testimony to enormous strides in the field. Patients who once would have died now live long enough to have cognitive side effects, just as survivors of childhood leukemia did many years ago, forcing new treatment protocols to avoid learning disabilities.

“A large number of people are living long and normal lives,” said Dr. Patricia Ganz, an oncologist at U.C.L.A. who is one of the nation’s first specialists in the late side effects of treatment. “It’s no longer enough to cure them. We have to acknowledge the potential consequences and address them early on.”

As researchers look for a cause, cancer survivors are trying to figure out how to get through the day by sharing their experiences, and by tapping expertise increasingly being offered online by Web sites like www.breastcancer.org and www.cancercare.org.

There are “ask the experts” teleconferences, both live and archived, and fact sheets to download and show to a skeptical doctor. Message boards suggest sharpening the mind with Japanese sudoku puzzles or compensatory techniques devised to help victims of brain injury. There are even sweatshirts for sale saying “I Have Chemo Brain. What’s Your Excuse?”

Studies of cognitive effects have overwhelmingly been conducted among breast cancer patients because they represent, by far, the largest group of cancer survivors and because they tend to be sophisticated advocates, challenging doctors and volunteering for research.

Most researchers studying cognitive deficits say they believe that those most inclined to notice even subtle changes are high-achieving women juggling careers and families who are used to succeeding at both. They point to one study that found that complaints of cognitive deficits often did not match the results of neuro-psychological tests, suggesting that chemo brain is a subjective experience.

“They say, ‘I’ve lost my edge,’ ” said Dr. Stewart Fleishman, director of cancer supportive services at Beth Israel and St. Luke’s/Roosevelt hospitals in New York. “If they can’t push themselves to the limit, they feel impaired.”

Dr. Fleishman and others were pressed as to why a poor woman, working several jobs to feed her children, navigating the health care system and battling insurance companies, would not also need mental dexterity. “Maybe we’re just not asking them,” Dr. Fleishman said.

Overall, middle-class cancer patients tend to get more aggressive treatment, participate in support groups, enroll in studies and use the Internet for research and community more than poor and minority patients, experts say.

“The disparity plays out in all kinds of ways,” said Ellen Coleman, the associate executive director of CancerCare, which provides free support services. “They don’t approach their health care person because they don’t expect help.”

But approaching a doctor does not guarantee help. Susan Mitchell, 48, who does freelance research on economic trends, complained to her oncologist in Jackson, Miss., that her income had been halved since her breast cancer treatment last year because everything took longer for her to accomplish.

She said his reply was a shrug.

“They see their job as keeping us alive, and we appreciate that,” Ms. Mitchell said. “But it’s like everything else is a luxury. These are survivor issues, and they need to get used to the fact that lots of us are surviving.”

Among women like Ms. Mitchell, lost A.T.M. cards are as common as missing socks. Children arrive at birthday parties a week early. Wet clothes wind up in the freezer instead of the dryer. Prosthetic breasts and wigs are misplaced at the most inopportune times. And simple words disappear from memory: “The thing with numbers” will have to do for the word “calculator.”

Linda Lowen, 46, had a hysterectomy and chemotherapy for ovarian cancer 13 years ago, and says she still cannot recognize neighbors at the grocery store. “I had a mind like a steel trap, and I ended up with a colander for a brain,” said Ms. Lowen, a radio and television talk show host in Syracuse.

The other night, Ms. Lowen set out to find a good place to store her knitting supplies. She began emptying a cabinet of games that her teenage daughters no longer played. Meanwhile, she noticed a blown light bulb and went to find a replacement. That detour led to another, and five hours later she had scrubbed every surface and tidied the contents of eight drawers. But she still had no storage space for her knitting supplies.

“I have an almost childlike inability to follow through on anything,” Ms. Lowen said.

Solutions come in many forms for women whose cancer treatment has left them with cognitive deficits.

Sedra Jayne Varga, 50, an administrative assistant in family court in Manhattan, is part of a research study of the stimulant Focalin, which she said had helped. But Ms. Varga also plans to have laser surgery on her eyes so that losing her glasses will no longer be an issue.

Lu Ann Hudson, 44, a designer of financial databases in Cincinnati, relies on a key fob that sets off a beep in her car when she is looking for it in parking lots. Terry-Lynne Jordan, 43, who analyzes environmental incidents for an oil company in Calgary, Alberta, uses the calendar on her computer and voice mail messages to herself to remind her of meetings.

And Debbie Kamplain, a 32-year-old stay-at-home mother in Peoria, Ill., hired a $30-an-hour personal organizer to help her sell a house, buy another and get ready to move her family to Indiana next month.

But it is Ms. Kamplain’s 2 ½-year-old son, Daniel, who sees to it that she stays on task. Long before Daniel could talk, he would pull her over to the refrigerator if she got distracted while getting him a drink.

“Poor kid,” Ms. Kamplain said. “I say I’m going to do something, forget about it immediately, and he’s the one who has to remind Mommy about stuff.”